Journal
NEUROENDOCRINOLOGY
Volume 109, Issue 1, Pages 34-41Publisher
KARGER
DOI: 10.1159/000499470
Keywords
Hyperprolactinemia; Pituitary tumor; Dopamine agonists; Bromocriptine; Cabergoline; Lisuride; Pergolide; Quinagolide
Categories
Ask authors/readers for more resources
The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting pituitary tumors, starting from the 1970s up to today, highlighting that normalization of PRL levels, restoration of eugonadism, and reduction of tumor mass can be achieved in the majority of patients by treatment with dopamine agonists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available